Canada
· Delayed Price · Currency is CAD Biocure Technology Statistics
Total Valuation
CSE:CURE.X has a market cap or net worth of CAD 3.76 million. The enterprise value is 3.78 million.
| Market Cap | 3.76M |
| Enterprise Value | 3.78M |
Important Dates
The next estimated earnings date is Tuesday, April 29, 2025.
| Earnings Date | Apr 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CSE:CURE.X has 94.00 million shares outstanding. The number of shares has decreased by -94.92% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 94.00M |
| Shares Change (YoY) | -94.92% |
| Shares Change (QoQ) | +800.00% |
| Owned by Insiders (%) | 0.74% |
| Owned by Institutions (%) | n/a |
| Float | 93.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.43 |
| P/TBV Ratio | 2.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 52.76 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.93 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07, with a Debt / Equity ratio of 0.03.
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -194.71% and return on invested capital (ROIC) is -28.05%.
| Return on Equity (ROE) | -194.71% |
| Return on Assets (ROA) | -21.82% |
| Return on Invested Capital (ROIC) | -28.05% |
| Return on Capital Employed (ROCE) | -59.97% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.37% in the last 52 weeks. The beta is 2.39, so CSE:CURE.X's price volatility has been higher than the market average.
| Beta (5Y) | 2.39 |
| 52-Week Price Change | -70.37% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 48.16 |
| Average Volume (20 Days) | 7,363 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -958,308 |
| Pretax Income | -4.03M |
| Net Income | -4.06M |
| EBITDA | n/a |
| EBIT | -958,308 |
| Earnings Per Share (EPS) | -1.06 |
Balance Sheet
The company has 26,776 in cash and 47,533 in debt, giving a net cash position of -20,757 or -0.00 per share.
| Cash & Cash Equivalents | 26,776 |
| Total Debt | 47,533 |
| Net Cash | -20,757 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 1.55M |
| Book Value Per Share | 0.02 |
| Working Capital | -367,595 |
Cash Flow
| Operating Cash Flow | 71,266 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CSE:CURE.X does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 94.92% |
| Shareholder Yield | 94.92% |
| Earnings Yield | -108.01% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 28, 2024. It was a reverse split with a ratio of 0.1111111.
| Last Split Date | Oct 28, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.1111111 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |